Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia

Ma, Qing
Cornelli, Umberto
Hanin, Israel
Jeske, Walter P.
Linhardt, Robert J.
Walenga, Jeanine M.
Fareed, Jawed
Lee, John M.
Thumbnail Image
Other Contributors
Issue Date
Biology , Chemistry and chemical biology , Chemical and biological engineering , Biomedical engineering
Terms of Use
In Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/
Full Citation
Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia, Q. Ma, U. Cornelli, I. Hanin, J. M. Lee, W. P. Jeske, R. J. Linhardt, J. M. Walenga, J. Fareed, Current Pharmaceutical Design, 13, 1607-1616, 2007.
Heparin is a glycosaminoglycan mixture currently used in prophylaxis and treatment of thrombosis. Heparin possesses non-anticoagulant properties, including modulation of various proteases, interactions with fibroblast growth factors, and anti-inflammatory actions. Senile dementia of Alzheimer’s type is accompanied by inflammatory responses contributing to irreversible changes in neuronal viability and brain function. Vascular factors are also involved in the pathogenesis of senile dementia. Inflammation, endogenous proteoglycans, and assembly of senile plagues and neurofibrillary tangles contribute directly and indirectly to further neuronal damage. Neuron salvage can be achieved by anti-inflammation and the competitive inhibition of proteoglycans accumulation. The complexity of the pathology of senile dementia provides numerous potential targets for therapeutic interventions designed to modulate inflammation and proteoglycan assembly. Heparin and related oligosaccharides are known to exhibit anti-inflammatory effects as well as inhibitory effects on proteoglycan assembly and may prove useful as neuroprotective agents.
Current Pharmaceutical Design, 13, 1607-1616
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
The Linhardt Research Labs.
The Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)
Bentham Science
The Linhardt Research Labs Online Collection
Rensselaer Polytechnic Institute, Troy, NY
Current Pharmaceutical Design
A full text version is available in DSpace@RPI